Abstract
Introduction
Galectin-3 is an endogenous galactose-binding protein that is expressed in a wide range of normal and neoplasic tissues and is thought to be involved in cellular adhesion, growth regulation, and apoptosis. Galectin-3 seems to have an important role in colorectal cancer. The aim of this study was to evaluate the immunoexpression of galectin-3 in patients with colorectal cancer under surgery and chemotherapy treatment and the relationship of galectin-3 expression and clinical aspects or tumor evolution.
Patients and Methods
Galectin-3 expression was examined immunohistochemically in 75 samples of colorectal tissues. A scoring system was used to evaluate the cytoplasmic cells color. Among the patients, 40 were female; the average age was 61.98 years old. According to the site, 42.6% was of the rectum, 33.4% right colon, and 24% left colon. Thirty-three tumors were stage II, 32 stage III, and ten stage IV.
Results and Discussion
Galectin-3 immunoexpression was classified as 1 in 57.33% of tumors. The highest percentage of staining cells appeared in the most advanced cancer (p = 0.4899). Patients with recurrence had a great number of tumors with high score (p = 0.0465). In addition, high or moderate galectin-3 immunoexpression had been associated with an increased marginal risk for death (p = 0.0795). The immunoexpression of galectin-3 was strong or moderate in 42% of the colorectal tumors. Patients with strong or moderate immunoexpression of galectin-3 died or had recurrence more frequently. The risk of death was marginally reduced in patients with negative or low-grade galectin-3. Galectin-3 cytoplasmatic immunoexpression seems to be a prognostic factor in colorectal cancer because a higher risk of recurrence had been observed in tumors with a high score of galectin-3. However, a higher risk of death was not found on this group.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell. 1994;76(4):597–8.
Hirabayashi J, Kasai K. The family of metazoan metal-independent beta-galactoside-binding lectins: structure, function and molecular evolution. Glycobiology. 1993;3(4):297–304.
Hughes RC. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochimica Acta. 1999;1473:172–85.
SanJuán X, Fernández PL, Castells A, Castronovo V, Van den Brule F, Liu FT, et al. Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology. 1997;113:1906–15.
Schoeppner HL, Raz A, Ho SB, Bresalier RS. Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer. 1995;75:2818–26.
Castronovo V, Campo E, Van der Brule FA, Claysmith AP, Cioce V, Fernandez LFR, et al. Inverse modulation of steady-state messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma. Journal of the National Cancer Institute. 1992;84:1161–9.
Castronovo V, Campo E, Van der Brule FA, Jackers P, Clausse N, Liu F, et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. The Journal of Pathology. 1996;179:43–8.
Haller DG, Catalano PJ, Macdonald JS, O’Rourke MA, Frontiera MS, Jackson DV, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. Journal of Clinical Oncology. 2005;23:8671–8.
Arfaoui-Toumi A, Kria-Ben Mahmoud L, Ben Hmida M, Khalfallah MT, Regaya-Mzabi S, Bouraoui S. Implication of the Galectin-3 in colorectal cancer development (about 325 Tunisian patients). Bulletin du Cancer. 2010;97(2):E1–8.
Liu HY, Huang ZL, Yang GH, Lu WQ, Yu NR. Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World Journal of Gastroenterology. 2008;14(48):7386–91.
Nakamura M, Inufusa H, Adachi T. Involvement of galectin-3 expression in colorectal cancer progression and metastasis. International Journal of Oncology. 1999;15:143–8.
Yoshimura A, Gemma A, Hosoya Y. Increased expression of the LGALS3 (galectin-3) gene in human non-small-cell lung cancer. Genes, Chromosomes & Cancer. 2003;37:159–64.
Inohara H, Honjo Y, Yoshii T, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer. 1998;5:2475–84.
Oka N, Takenaka Y, Raz A. Galectins and urological cancer. Journal of Cellular Biochemistry. 2004;91:118–24.
Califice S, Castronovo V, Van den Brole F. Galectin-3 and cancer. International Journal of Oncology. 2004;25:983–92.
Schwarz Jr G, Remmelink M, Decaestecker C. Galectin fingerprinting in tumor diagnosis. Differential expression of galectin-3 and galectin-3 binding sites, but not galectin-1, in benign vs. malignant uterine smooth muscle tumors. American Journal of Clinical Pathology. 1999;111:623–31.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA: A Cancer Journal for Clinicians. 2007;57:43–66.
Roque VMN, Forones NM. Avaliação da qualidade de vida e toxicidades em pacientes com câncer colorretal tratados com quimioterapia adjuvante baseada em fluoropirimidinas. Arquivos de Gastroenterologia. 2006;43(2):94–101.
Disclosures
No conflicts of interest exist.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zaia Povegliano, L., Oshima, C.T.F., de Oliveira Lima, F. et al. Immunoexpression of Galectin-3 in Colorectal Cancer and its Relationship with Survival. J Gastrointest Canc 42, 217–221 (2011). https://doi.org/10.1007/s12029-010-9189-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-010-9189-1